Progressive multifocal leukoencephalopathy: Can we reduce risk in patients receiving biological immunomodulatory therapies?
- 31 August 2010
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 68 (3) , 271-274
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- JC Virus Latency in the Brain and Extraneural Organs of Patients with and without Progressive Multifocal LeukoencephalopathyJournal of Virology, 2010
- JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2010
- Human Polyomavirus JC (JCV) Infection of Human B Lymphocytes: A Possible Mechanism for JCV Transmigration across the Blood‐Brain BarrierThe Journal of Infectious Diseases, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory TherapiesAnnual Review of Medicine, 2010
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabNew England Journal of Medicine, 2009
- Seroepidemiology of Human PolyomavirusesPLOS Pathogens, 2009
- Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV‐Positive and HIV‐Negative Patients: Implications for Viral Latency and Neurotropic TransformationThe Journal of Infectious Diseases, 2009
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Detection of JC virus DNA fragments but not proteins in normal brain tissueAnnals of Neurology, 2008